Cargando…

Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()

The COVID-19 pandemic adversely impacted economic activity, decreased corporate revenues, and magnified cash flow fluctuations. We study how Chinese listed firms' COVID exposure influences their cash holdings. A firm's COVID exposure is measured by its excess stock return responses to glob...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhongda, Suardi, Sandy, Wang, Kai, Zhao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392874/
https://www.ncbi.nlm.nih.gov/pubmed/36032988
http://dx.doi.org/10.1016/j.econmod.2022.105999
_version_ 1784771154707218432
author He, Zhongda
Suardi, Sandy
Wang, Kai
Zhao, Yang
author_facet He, Zhongda
Suardi, Sandy
Wang, Kai
Zhao, Yang
author_sort He, Zhongda
collection PubMed
description The COVID-19 pandemic adversely impacted economic activity, decreased corporate revenues, and magnified cash flow fluctuations. We study how Chinese listed firms' COVID exposure influences their cash holdings. A firm's COVID exposure is measured by its excess stock return responses to globally newly infected cases while controlling for market return. Firms increase (decrease) cash balances when their stock returns fall (increase) with COVID severity due to precautionary motives. Firms cannot predict the evolution of the pandemic, which impacts demand and supply and the cash conversion cycle. The deteriorating business condition also increases external financing costs with non-state-owned, low-growth, small, and firms without overseas businesses facing higher financial frictions. Furthermore, firms with good corporate governance tend to pre-empt operational uncertainty by increasing cash holdings. The increased cash holdings translate to more R&D expenditure but lesser capital investment. Our results remain robust to placebo tests, using excess cash and alternative COVID exposure measures.
format Online
Article
Text
id pubmed-9392874
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-93928742022-08-22 Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China() He, Zhongda Suardi, Sandy Wang, Kai Zhao, Yang Econ Model Article The COVID-19 pandemic adversely impacted economic activity, decreased corporate revenues, and magnified cash flow fluctuations. We study how Chinese listed firms' COVID exposure influences their cash holdings. A firm's COVID exposure is measured by its excess stock return responses to globally newly infected cases while controlling for market return. Firms increase (decrease) cash balances when their stock returns fall (increase) with COVID severity due to precautionary motives. Firms cannot predict the evolution of the pandemic, which impacts demand and supply and the cash conversion cycle. The deteriorating business condition also increases external financing costs with non-state-owned, low-growth, small, and firms without overseas businesses facing higher financial frictions. Furthermore, firms with good corporate governance tend to pre-empt operational uncertainty by increasing cash holdings. The increased cash holdings translate to more R&D expenditure but lesser capital investment. Our results remain robust to placebo tests, using excess cash and alternative COVID exposure measures. Elsevier B.V. 2022-11 2022-08-21 /pmc/articles/PMC9392874/ /pubmed/36032988 http://dx.doi.org/10.1016/j.econmod.2022.105999 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
He, Zhongda
Suardi, Sandy
Wang, Kai
Zhao, Yang
Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title_full Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title_fullStr Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title_full_unstemmed Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title_short Firms’ COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China()
title_sort firms’ covid-19 pandemic exposure and corporate cash policy: evidence from china()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392874/
https://www.ncbi.nlm.nih.gov/pubmed/36032988
http://dx.doi.org/10.1016/j.econmod.2022.105999
work_keys_str_mv AT hezhongda firmscovid19pandemicexposureandcorporatecashpolicyevidencefromchina
AT suardisandy firmscovid19pandemicexposureandcorporatecashpolicyevidencefromchina
AT wangkai firmscovid19pandemicexposureandcorporatecashpolicyevidencefromchina
AT zhaoyang firmscovid19pandemicexposureandcorporatecashpolicyevidencefromchina